Methylallyltryptamine (MALT), also known as N-methyl-N-allyltryptamine, is a lesser-known psychedelic drug from the tryptamine family.[1] It is a novel compound with very little history of human use.[1] It is closely related to methylpropyltryptamine (MPT).[1] The drug has been sold online as a designer drug.[1] Very little information on the pharmacology or toxicity of MALT is available.[citation needed]

Use and effects

MALT was not included in Alexander Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved).[2] However, years after the book's publication, he described MALT as having important unexplored potential as a psychedelic drug.[3] Subsequently, MALT was encountered as a novel designer drug.[1] It has been reported to have been used at doses of 25 to 50 mg via routes including oral, smoking, or vaping.[1] The drug's effects have been described as comparable to those of methylpropyltryptamine (MPT) but less pronounced.[1]

Interactions

See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Pharmacology

Pharmacodynamics

MALT is a serotonin receptor modulator and has been found to interact with the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors.[4]

Chemistry

Analogues

Analogues of MALT include 4-HO-MALT, 4-AcO-MALT, 5-MeO-MALT, diallyltryptamine (DALT), methylpropyltryptamine (MPT), and methylisopropyltryptamine (MiPT), among others.

History

MALT was first described in the scientific literature by Niels Jensen of the University of Göttingen by 2004.[4] The drug was subsequently first encountered as a novel designer drug by 2018.[1]

Society and culture

MALT Crystals
A ziplock bag containing 100mg of MALT crystals, labeled "Not for human consumption".

MALT is not explicitly scheduled in any countries; however, it could be considered a psychoactive substance under the United Kingdom Psychoactive Substances Act, which requires the prosecutor to prove that the substance is psychoactive in order for a person to be charged with an offense.[5] It could also be considered a structural analogue of a scheduled substance under the United States Federal Analogue Act due to its similarity to scheduled tryptamines. It is not a controlled substance in Canada as of 2025.[6]

See also

References

  1. ^ a b c d e f g h i j k "MALT". АИПСИН (in Russian). Retrieved 2 January 2026.
  2. ^ a b c Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
  3. ^ Morris H (2014). "Alexander Shulgin (1925–2014)". The Fabulist. No. 5. On that day in 2010, Alexander Shulgin was sitting outside under a parasol in his front yard surrounded by admirers, looking very happy, and talking discursively about the unexplored potential in 5-ethoxylated tryptamines and asymmetrical N-allyl-tryptamines such as MAlT, EAlT, PAlT, and iPAlT
  4. ^ a b Jensen N (2004). Tryptamines as Ligands and Modulators of the Serotonin 5‑HT2A Receptor and the Isolation of Aeruginascin from the Hallucinogenic Mushroom Inocybe aeruginascens (PDF) (Thesis). Georg-August-University Göttingen. doi:10.53846/goediss-2111.
  5. ^ "Psychoactive Substances Act Guidance" (PDF). The Crown Prosecution Service. Retrieved 2021-09-23.
  6. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
source: https://en.wikipedia.org/wiki/Methylallyltryptamine